# BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

> **NCT00459667** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 1420 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)
- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)
- **DRUG:** Interferon beta-1b (Betaseron, BAY86-5046)

## Key facts

- **NCT ID:** NCT00459667
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 1420 (ACTUAL)
- **Last updated:** 2015-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00459667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00459667, "BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00459667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*